INmune Bio(US:INMB) Globenewswire·2025-10-30 20:05Core Insights - INmune Bio Inc. reported its financial results for Q3 2025, highlighting advancements in its clinical programs and a significant reduction in net loss compared to the previous year [1][10]. Financial Performance - The net loss attributable to common stockholders for Q3 2025 was approximately $6.5 million, a decrease from approximately $12.1 million in Q3 2024 [10]. - Research and development expenses totaled approximately $4.9 million for Q3 2025, down from approximately $10.1 million in Q3 2024 [10]. - General and administrative expenses were approximately $2.5 million for Q3 2025, compared to approximately $2.2 million in Q3 2024 [10]. - As of September 30, 2025, the company had cash and cash equivalents of approximately $27.7 million [10]. Product Development Highlights - The CORDStrom™ platform successfully completed its first two commercial pilot-scale manufacturing runs, with plans to file a Marketing Authorization Application (MAA) in mid-2026 for recessive dystrophic epidermolysis bullosa (RDEB) [5]. - XPro™, a selective soluble TNF neutralizer, showed promising results in a Phase 2 trial for early Alzheimer's disease, demonstrating cognitive benefits and a favorable safety profile [5][11]. - The INKmune® platform is currently in a Phase I/II trial for metastatic castration-resistant prostate cancer, with data expected to be released in Q4 2025 [12][10]. Corporate Updates - Dr. RJ Tesi retired, and David Moss was appointed as the new President & CEO [10]. - Cory Ellspermann was appointed as CFO, and Kelly Ganjei was named Chairman of the board of directors [10]. - The company plans to present additional data on CORDStrom™ and imaging data from the Phase 2 MINDFuL trial in Q4 2025 [10].